NCT01071135

Quetiapine XR in Schizophrenic Patients

Effects of Quetiapine XR in Schizophrenic Patients With Cannabis Abuse and/or Cannabis Induced Psychosis -Pilot Study-

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Hannover Medical School · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine the effect of Quetiapine in patients with schizophrenia induced by cannabis abuse.

Detailed description

To evaluate the effect of quetiapine on positive and negative symptoms of schizophrenia on schizophrenic patients associated with cannabis abuse and patients with psychotic disorders through cannabis abuse.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Quetiapine XR	Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.

Timeline

• Start date: 2009-09-01
• Primary completion: 2010-08-01
• Completion: 2010-08-01
• First posted: 2010-02-19
• Last updated: 2011-11-11

Locations

3 sites across 1 country: Germany